Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP1707 in healthy Japanese males
NCT02146742Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Jun 2011
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of opigolix in endometriosis (3 cohorts), sponsored by Astellas Pharma. Primary endpoints: Adverse events at 19 days, Physical examination at 19 days and 3 more. Started Jun 2011; status: completed.
02
Drugs
opigolix
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT02146742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02146742.